BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tsubota M, Fukuda R, Hayashi Y, Miyazaki T, Ueda S, Yamashita R, Koike N, Sekiguchi F, Wake H, Wakatsuki S, Ujiie Y, Araki T, Nishibori M, Kawabata A. Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin/thrombomodulin system in rodents: negative impact of anticoagulants. J Neuroinflammation 2019;16:199. [PMID: 31666085 DOI: 10.1186/s12974-019-1581-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Uhelski ML, Li Y, Fonseca MM, Romero-Snadoval EA, Dougherty PM. Role of innate immunity in chemotherapy-induced peripheral neuropathy. Neurosci Lett 2021;755:135941. [PMID: 33961945 DOI: 10.1016/j.neulet.2021.135941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Meng L, Huang J, Qiu F, Shan X, Chen L, Sun S, Wang Y, Yang J. Peripheral Neuropathy During Concomitant Administration of Proteasome Inhibitors and Factor Xa Inhibitors: Identifying the Likelihood of Drug-Drug Interactions. Front Pharmacol 2022;13:757415. [DOI: 10.3389/fphar.2022.757415] [Reference Citation Analysis]
3 Tsubota M, Miyazaki T, Ikeda Y, Hayashi Y, Aokiba Y, Tomita S, Sekiguchi F, Wang D, Nishibori M, Kawabata A. Caspase-Dependent HMGB1 Release from Macrophages Participates in Peripheral Neuropathy Caused by Bortezomib, a Proteasome-Inhibiting Chemotherapeutic Agent, in Mice. Cells 2021;10:2550. [PMID: 34685531 DOI: 10.3390/cells10102550] [Reference Citation Analysis]
4 Muhammad S, Chaudhry SR, Kahlert UD, Lehecka M, Korja M, Niemelä M, Hänggi D. Targeting High Mobility Group Box 1 in Subarachnoid Hemorrhage: A Systematic Review. Int J Mol Sci 2020;21:E2709. [PMID: 32295146 DOI: 10.3390/ijms21082709] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
5 Wang X, Ye L, He W, Teng C, Sun S, Lu H, Li S, Lv L, Cao X, Yin H, Lv W, Xin H. In situ targeting nanoparticles-hydrogel hybrid system for combined chemo-immunotherapy of glioma. J Control Release 2022;345:786-97. [PMID: 35367277 DOI: 10.1016/j.jconrel.2022.03.050] [Reference Citation Analysis]
6 Sekiguchi F, Kawabata A. Role of HMGB1 in Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci 2020;22:E367. [PMID: 33396481 DOI: 10.3390/ijms22010367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Fumagalli G, Monza L, Cavaletti G, Rigolio R, Meregalli C. Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy. Front Immunol 2020;11:626687. [PMID: 33613570 DOI: 10.3389/fimmu.2020.626687] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Lai HJ, Zhan YQ, Qiu YX, Ling YH, Zhang XY, Chang ZN, Zhang YN, Liu ZM, Wen SH. HMGB1 signaling-regulated endoplasmic reticulum stress mediates intestinal ischemia/reperfusion-induced acute renal damage. Surgery 2021;170:239-48. [PMID: 33745733 DOI: 10.1016/j.surg.2021.01.042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yang Y, Zhao B, Gao X, Sun J, Ye J, Li J, Cao P. Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development. J Exp Clin Cancer Res 2021;40:331. [PMID: 34686205 DOI: 10.1186/s13046-021-02141-z] [Reference Citation Analysis]
10 Kotaka M, Saito Y, Kato T, Satake H, Makiyama A, Tsuji Y, Shinozaki K, Fujiwara T, Mizushima T, Harihara Y, Nagata N, Kurihara N, Ando M, Kusakawa G, Sakai T, Uchida Y, Takamoto M, Kimoto S, Hyodo I. A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy. Cancer Chemother Pharmacol 2020;86:607-18. [PMID: 32965539 DOI: 10.1007/s00280-020-04135-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Miyamoto T, Domoto R, Sekiguchi F, Kamaguchi R, Nishimura R, Matsuno M, Tsubota M, Fujitani M, Hatanaka S, Koizumi Y, Wang D, Nishibori M, Kawabata A. Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies. Journal of Pharmacological Sciences 2022. [DOI: 10.1016/j.jphs.2022.01.006] [Reference Citation Analysis]
12 Minami T, Takeda M, Sata M, Kato H, Yano K, Sakai T, Tsujita R, Kawasaki K, Ito A. Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity. Eur J Pharmacol 2020;880:173196. [PMID: 32416186 DOI: 10.1016/j.ejphar.2020.173196] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
13 Tomita S, Sekiguchi F, Kasanami Y, Naoe K, Tsubota M, Wake H, Nishibori M, Kawabata A. Cav3.2 overexpression in L4 dorsal root ganglion neurons after L5 spinal nerve cutting involves Egr-1, USP5 and HMGB1 in rats: An emerging signaling pathway for neuropathic pain. Eur J Pharmacol 2020;888:173587. [PMID: 32971090 DOI: 10.1016/j.ejphar.2020.173587] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Sałat K. Chemotherapy-induced peripheral neuropathy-part 2: focus on the prevention of oxaliplatin-induced neurotoxicity. Pharmacol Rep 2020;72:508-27. [PMID: 32347537 DOI: 10.1007/s43440-020-00106-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
15 Hiramoto S, Asano H, Miyamoto T, Takegami M, Kawabata A. Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan. PLoS One 2021;16:e0261473. [PMID: 34972132 DOI: 10.1371/journal.pone.0261473] [Reference Citation Analysis]
16 Hiramoto S, Tsubota M, Yamaguchi K, Okazaki K, Sakaegi A, Toriyama Y, Tanaka J, Sekiguchi F, Ishikura H, Wake H, Nishibori M, Nguyen HD, Okada T, Toyooka N, Kawabata A. Cystitis-Related Bladder Pain Involves ATP-Dependent HMGB1 Release from Macrophages and Its Downstream H2S/Cav3.2 Signaling in Mice. Cells 2020;9:E1748. [PMID: 32707767 DOI: 10.3390/cells9081748] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
17 Cavaletti G, Marmiroli P. Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy. Cancers (Basel) 2020;12:E1370. [PMID: 32471028 DOI: 10.3390/cancers12061370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
18 Yamamoto S, Egashira N. Drug Repositioning for the Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Mechanism- and Screening-Based Strategy. Front Pharmacol 2020;11:607780. [PMID: 33519471 DOI: 10.3389/fphar.2020.607780] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Okui T, Hiasa M, Ryumon S, Ono K, Kunisada Y, Ibaragi S, Sasaki A, Roodman GD, White FA, Yoneda T. The HMGB1/RAGE axis induces bone pain associated with colonization of 4T1 mouse breast cancer in bone. J Bone Oncol 2021;26:100330. [PMID: 33204606 DOI: 10.1016/j.jbo.2020.100330] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Tsujita R, Tsubota M, Sekiguchi F, Kawabata A. Role of high-mobility group box 1 and its modulation by thrombomodulin/thrombin axis in neuropathic and inflammatory pain. Br J Pharmacol 2021;178:798-812. [PMID: 32374414 DOI: 10.1111/bph.15091] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
21 Irie Y, Tsubota M, Maeda M, Hiramoto S, Sekiguchi F, Ishikura H, Wake H, Nishibori M, Kawabata A. HMGB1 and its membrane receptors as therapeutic targets in an intravesical substance P-induced bladder pain syndrome mouse model. J Pharmacol Sci 2020;143:112-6. [PMID: 32222337 DOI: 10.1016/j.jphs.2020.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Domoto R, Sekiguchi F, Tsubota M, Kawabata A. Macrophage as a Peripheral Pain Regulator. Cells 2021;10:1881. [PMID: 34440650 DOI: 10.3390/cells10081881] [Reference Citation Analysis]
23 Domoto R, Sekiguchi F, Kamaguchi R, Iemura M, Yamanishi H, Tsubota M, Wang D, Nishibori M, Kawabata A. Role of neuron-derived ATP in paclitaxel-induced HMGB1 release from macrophages and peripheral neuropathy. J Pharmacol Sci 2022;148:156-61. [PMID: 34924121 DOI: 10.1016/j.jphs.2021.11.003] [Reference Citation Analysis]
24 Kawashiri T, Mine K, Kobayashi D, Inoue M, Ushio S, Uchida M, Egashira N, Shimazoe T. Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence. Int J Mol Sci 2021;22:1393. [PMID: 33573316 DOI: 10.3390/ijms22031393] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Miyamoto T, Hiramoto S, Kanto A, Tsubota M, Fujitani M, Fukuyama H, Hatanaka S, Sekiguchi F, Koizumi Y, Kawabata A. Estrogen decline is a risk factor for paclitaxel-induced peripheral neuropathy: Clinical evidence supported by a preclinical study. J Pharmacol Sci 2021;146:49-57. [PMID: 33858655 DOI: 10.1016/j.jphs.2021.03.001] [Reference Citation Analysis]